{
    "clinical_study": {
        "@rank": "142853", 
        "arm_group": [
            {
                "arm_group_label": "ASP3652 Group 1", 
                "arm_group_type": "Experimental", 
                "description": "Dosed according to the following scheme: placebo, low dose, medium dose, high dose"
            }, 
            {
                "arm_group_label": "ASP3652  Group 2", 
                "arm_group_type": "Experimental", 
                "description": "Dosed according to the following scheme: low dose, placebo, medium dose, high dose"
            }, 
            {
                "arm_group_label": "ASP3652 Group 3", 
                "arm_group_type": "Experimental", 
                "description": "Dosed according to the following scheme: low dose, medium dose, placebo, high dose"
            }, 
            {
                "arm_group_label": "ASP3652 Group 4", 
                "arm_group_type": "Experimental", 
                "description": "Dosed according to the following scheme: low dose, medium dose, high dose, placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to explore the safety (including the effect on cardiac\n      intervals), tolerability, the effects on the Central Nervous System (CNS), as well as the\n      CNS side effect profile of single ascending doses of ASP3652 in healthy, Caucasian male and\n      female subjects."
        }, 
        "brief_title": "A Study to Assess the Safety, Tolerability and Effects of Single Ascending Doses of ASP3652 in Healthy Subjects", 
        "completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "condition": [
            "Pharmacokinetics", 
            "Pharmacodynamics", 
            "Healthy Subjects", 
            "Safety"
        ], 
        "detailed_description": {
            "textblock": "Each subject receives 3 single ascending doses of ASP3652 and a single dose of matching\n      placebo during one randomly selected investigational period. Randomization is conducted\n      separately for males and females.\n\n      The washout period between dosing occasions is at least 7 days. Screening takes place from\n      Day -22 to Day -2. Subjects are admitted to the clinic in the afternoon of Day -1 of\n      investigational period 1, 2, 3 and 4 for pre-dose assessments.\n\n      On Day -1 of all investigational periods, subjects do not take any food or drink for at\n      least 10 hours before the anticipated dosing time on Day 1. For the duration of their stay\n      in the clinic, subjects are not allowed to consume caffeine or other xanthine-containing\n      drinks.\n\n      The  subjects are discharged on Day 4 of each investigational period. The End of Study Visit\n       (ESV) is planned to take place 7-14 days after early discharge or after Day 4 of\n      investigational period 4."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject is white and of Caucasian origin.\n\n          -  Body Mass Index more than or equal to 18.5 and less than 30.0kg/m2.\n\n          -  Male subject must agree to practice an adequate contraceptive method with female\n             sexual partners to prevent pregnancy.\n\n          -  Female subject must agree to practice an adequate contraceptive method with male\n             sexual partners to prevent pregnancy.\n\n        Exclusion Criteria:\n\n          -  Pregnancy within 6 months before screening assessment or breast feeding within 3\n             months before screening (for females subjects only).\n\n          -  Known or suspected hypersensitivity to ASP3652, or any components of the formulation\n             used.\n\n          -  A mean QTc(F) interval of >430 ms (for males) and >450 ms (for females) after\n             triplicate measurements, a history of unexplained syncope, cardiac arrest,\n             unexplained cardiac arrhythmias or torsades de pointes, structural heart disease, or\n             a family history of Long QT Syndrome (LQTS). In case of an abnormal QTc(F) interval,\n             the assessment may be repeated once (in triplicate). If the QTc(F) interval exceeds\n             the limits, two additional Electrocardiogram (ECG)s can be recorded and the average\n             of the three QTc(F) values should be used to determine the subject's eligibility."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "26", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01815684", 
            "org_study_id": "3652-CL-0049", 
            "secondary_id": "2011-004247-41"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "ASP3652 Group 1", 
                    "ASP3652  Group 2", 
                    "ASP3652 Group 3", 
                    "ASP3652 Group 4"
                ], 
                "description": "Oral", 
                "intervention_name": "ASP3652", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "ASP3652 Group 1", 
                    "ASP3652  Group 2", 
                    "ASP3652 Group 3", 
                    "ASP3652 Group 4"
                ], 
                "description": "Oral", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Phase I", 
            "ASP3652", 
            "Dose escalation", 
            "Maximum Tolerated Dose (MTD)"
        ], 
        "lastchanged_date": "March 19, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Leiden", 
                    "country": "Netherlands", 
                    "zip": "2333CL"
                }, 
                "name": "Centre for Human Drug Research"
            }
        }, 
        "location_countries": {
            "country": "Netherlands"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Phase I, Double Blind, Placebo-controlled, Randomized 4-way Alternating Cross-over Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of Single Ascending Doses of ASP3652 in Healthy Young Caucasian Male and Female Subjects", 
        "overall_official": {
            "affiliation": "Astellas Pharma Europe B.V.", 
            "last_name": "Study Manager", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Safety and tolerability of single ascending doses of ASP3652 assessed through vital signs, adverse events, electrocardiogram and clinical laboratory assessments", 
                "safety_issue": "Yes", 
                "time_frame": "Day -22  to ESV (7-14 days after (early) discharge)"
            }, 
            {
                "description": "QT (Q wave to T wave)/QTc interval (QT interval corrected for heart rate), QT interval, RR (R wave to R wave) interval, HR (Heart Rate), PR interval, QRS interval, QTcB, QTcF", 
                "measure": "Safety and tolerability of single ascending doses of ASP3652 assessed through electrocardiogram", 
                "safety_issue": "Yes", 
                "time_frame": "Day -22  to ESV (7-14 days after (early) discharge)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01815684"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Plasma: Cmax (Maximum concentration), AUClast (AUC until last sample taken), AUCinf (AUC extrapolated until infinity), tmax (Time to attain Cmax), tlag (Absorption lag time), t1/2 (Apparent terminal elimination half-life), Vz/F (Apparent volume of distribution), CL/F (Apparent total body plasma clearance)/ Urine: Aelast (Amount excreted in urine until last sample), Aeinf (Cumulative amount of unchanged drug excreted into the urine from time zero to infinity after single dose), Aelast% (Percentage of unchanged drug excreted into the urine from time of last measurable concentration), Aeinf% (Percentage of unchanged drug excreted into the urine from time zero to infinity after single dose), CLR (Renal clearance)", 
                "measure": "Pharmacokinetic profile of single ascending doses of ASP3652", 
                "safety_issue": "No", 
                "time_frame": "Days 1- 4 (Investigational period 1 - 4)"
            }, 
            {
                "description": "Body sway, alertness, perception, mood, learning, memory, distraction, adaptive tracking, eye movements, addiction, neuro-endocrine parameters", 
                "measure": "Effect of single ascending doses of ASP3652 on CNS Pharmacodynamics", 
                "safety_issue": "No", 
                "time_frame": "Days 1 - 4 (Investigational period 1 - 4)"
            }, 
            {
                "description": "Rmax, tmax R, AUR", 
                "measure": "Effect of single ascending doses of ASP3652 on plasma levels of enzyme substrates", 
                "safety_issue": "No", 
                "time_frame": "Days 1 - 4 (Investigational period 1 - 4)"
            }
        ], 
        "source": "Astellas Pharma Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Astellas Pharma Europe B.V.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}